Universe Pharmaceuticals Inc (UPC) - Total Liabilities
Based on the latest financial reports, Universe Pharmaceuticals Inc (UPC) has total liabilities worth $13.17 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Universe Pharmaceuticals Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Universe Pharmaceuticals Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Universe Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see UPC total asset value.
Universe Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Universe Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tivic Health Systems Inc
NASDAQ:TIVC
|
USA | $27.15 Million |
|
Atomic Minerals Corp
V:ATOM
|
Canada | CA$1.15 Million |
|
Yangaroo Inc
V:YOO
|
Canada | CA$3.79 Million |
|
RBR Group Ltd
AU:RBR
|
Australia | AU$2.08 Million |
|
BioXcel Therapeutics Inc
NASDAQ:BTAI
|
USA | $139.57 Million |
|
Anatara Lifesciences Ltd
AU:ANR
|
Australia | AU$612.42K |
|
Mantex AB
ST:MANTEX
|
Sweden | Skr16.40 Million |
|
Lazydays Holdings Inc
NASDAQ:GORV
|
USA | $359.47 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Universe Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See UPC equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Universe Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Universe Pharmaceuticals Inc (2018–2025)
The table below shows the annual total liabilities of Universe Pharmaceuticals Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $13.17 Million | -41.32% |
| 2024-09-30 | $22.45 Million | +63.22% |
| 2023-09-30 | $13.75 Million | +5.01% |
| 2022-09-30 | $13.10 Million | +16.83% |
| 2021-09-30 | $11.21 Million | +40.11% |
| 2020-09-30 | $8.00 Million | +46.74% |
| 2019-09-30 | $5.45 Million | -70.36% |
| 2018-09-30 | $18.40 Million | -- |
About Universe Pharmaceuticals Inc
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong … Read more